BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Said vs. Filed

CorMedix’s Reimbursement Cliff Meets a $145 Million Bet: What the Call Said, What the Filing Confirmed

Moe Alsumidaie by Moe Alsumidaie
November 16, 2026
in Said vs. Filed
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

An analyst asked the question that was sitting in every listener’s mind. On the Q3 2026 earnings call on November 12, with revenue having fallen nearly in half from a year earlier, the exchange went to the heart of the matter: if CMS can reset DefenCath’s reimbursement rate every quarter, how does management guide for 2027? CEO Joseph Todisco’s answer was, in effect, that it cannot. CorMedix withdrew its 2027 DefenCath revenue guidance entirely, citing the new quarterly-reset methodology. Every other number on the call orbits that admission.

In one breath

CorMedix spent years as a pre-revenue biotech and turned profitable in 2025, driven by DefenCath’s launch and the Melinta acquisition. The 10-Q filed November 12 shows Q3 2026 revenue nearly cut in half from the same quarter a year ago, because a government pricing rule changed on July 1. Management reaffirmed full-year 2026 guidance but pulled its 2027 product-specific forecast. The stock sits well below where it traded twelve months ago. The math says the business is generating real cash; the mood says the market does not yet trust what that cash will look like next year.

How a company goes from zero to hundreds of millions in one year

For most of its life, CorMedix earned essentially nothing. Our data show negligible revenue in each year from 2020 through 2023, with losses compounding quietly. The turning point arrived on November 15, 2023, when the FDA approved DefenCath, a catheter-locking solution that reduces bloodstream infections in hemodialysis patients. Think of it as a rinse used between dialysis sessions to keep the catheter clean, a simple intervention in a setting where infections can be fatal.

Commercial launch followed in inpatient settings in April 2024 and outpatient dialysis clinics in July 2024. Then, in August 2025, CorMedix acquired Melinta Therapeutics, adding a portfolio of acute-care antibiotics including REZZAYO, an antifungal. The 10-K for fiscal year 2025 records the result: $312 million in revenue and a net margin of 52%, the first profitable year in the company’s history. A business that had been burning cash for a decade had, in roughly eighteen months, become one that generated more than it spent.

BullScope TerminalYou just read CorMedix’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

That context matters because the stock’s steep decline over the past twelve months is not a story about a failing business. It is a story about what happens when the pricing rule that powered the launch changes.

The cliff that arrived July 1

DefenCath’s early commercial success rested on a Medicare program called TDAPA, the Transitional Drug Add-on Payment Adjustment. TDAPA is a temporary premium that Medicare pays for newly approved drugs used in dialysis, designed to encourage adoption. It is generous by construction and, by design, temporary. On July 1, 2026, DefenCath’s TDAPA period ended.

What replaced it was a sharply lower add-on payment per dialysis session, set by CMS for the second half of 2026. The Q3 2026 10-Q shows the consequence directly: DefenCath net sales of $17.2 million for the quarter, against consolidated revenue of $54.5 million that included $31.4 million from the Melinta portfolio. A year earlier, in Q3 2025, consolidated revenue was $104.3 million. The drop is almost entirely a pricing story, not a volume story. The filing notes that outpatient dialysis customers largely maintained their utilization rates, meaning clinics kept using the product; they just paid less for it.

The underlying demand held, but the price the company receives per use fell sharply, and that gap is the whole revenue story for the quarter.

The exchange that defined the call

The withdrawal of 2027 DefenCath guidance was the sharpest moment on the November 12 call. CMS, in its October 28 ESRD final rule, established not just a new rate but a new process: the add-on payment will reset every quarter based on actual utilization data. That makes annual forecasting genuinely difficult. Management said the Q1 2027 rate would be more than triple the current rate, and that the full-year 2027 average should be at least double. But it declined to put a revenue number on that expectation, because each subsequent quarter’s rate is unknown until CMS sets it.

BullScope TerminalCorMedix was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

That is an honest answer. It is also an uncomfortable one for investors who want a number to model. The tension between those two facts explains much of the stock’s mood.

The $145 million response

Three days before the earnings call, on November 9, CorMedix announced a deal to acquire substantially all assets of Heron Therapeutics for $145 million in cash plus roughly 14.6 million common shares. The transaction is expected to close in Q1 2027. Management said the Heron assets would add between $125 million and $150 million in pro forma 2027 revenue and generate $45 million to $60 million in annualized operating cost savings by the end of 2027.

The strategic logic is straightforward: if one product’s revenue is now subject to quarterly government resets, owning more products reduces the damage any single reset can cause. Needham, revising its valuation estimate on November 10, called the Heron assets a “strategic fit” that “should help diversification to cushion volatility in DefenCath sales.” RBC Capital, maintaining an Outperform rating, moved its estimate higher on November 11. Both analysts are expressing a view; BullScope is reporting theirs, not endorsing it.

What the filing confirms is that CorMedix held $355.2 million in cash as of September 30, 2026, more than twice the cash portion of the Heron purchase price. The company can write the check without raising equity. Whether the assets it is buying justify the price is a question the filed numbers cannot yet answer, because Heron’s contribution will not appear in a CorMedix filing until after the deal closes.

What held up, what did not

Management’s full-year 2026 revenue guidance of $325 million to $345 million was reaffirmed on the call and is consistent with the quarterly revenue trend reported in the filed 10-Q. The narrowed adjusted EBITDA guidance similarly tracks the filed trend. Those numbers held up.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: CorMedix and 500+ other names, on the same official data.See the evidence engine →

What did not hold up was the implicit assumption, present in earlier investor communications, that DefenCath’s post-TDAPA reimbursement would be stable enough to forecast. The new quarterly-reset mechanism, formalized in the CMS October 28 final rule, makes that impossible. Management was right to withdraw the guidance rather than invent a number; the filing’s risk disclosures now reflect that uncertainty explicitly.

One additional item from the 10-Q filed November 12 worth noting: the FDA accepted for priority review an sNDA for REZZAYO in fungal prophylaxis on October 19, 2026, with a target action date in Q1 2027. If approved, REZZAYO would expand from treatment into prevention, a larger and more recurring market. The filing records the acceptance; it cannot record the outcome.

Reading the numbers

  • $54.5 million, Q3 2026 consolidated revenue (10-Q, September 30, 2026). This is what the company collected from all products in the quarter. It is roughly half of Q3 2025’s $104.3 million. Think of a shop that kept its foot traffic but cut its prices in half on its best-selling item: the customers came back, but the register rang up less.
  • $17.2 million, DefenCath net sales in Q3 2026, including a $5.0 million favorable adjustment for Medicaid rebate and product return allowances. Strip that adjustment out and the underlying number is closer to $12 million. That is what a single pricing-rule change did to the company’s flagship product in one quarter.
  • $2.37 to $8.32, the CMS add-on payment shift. The $2.37 rate applied per dialysis session in Q3 and Q4 2026; the $8.32 rate takes effect Q1 2027. A dialysis patient typically attends three sessions a week. At $2.37, a clinic collects roughly $7 per patient per week for using DefenCath; at $8.32, it collects roughly $25. That difference determines how attractive the product is to prescribe.
  • $355.2 million in cash as of September 30, 2026. The Heron deal costs $145 million in cash. After closing, the company would hold roughly $210 million in cash, assuming no other material changes, more than enough to fund operations through the integration period.
  • P/E of 2.4, against a decade median of 3.8 (our data). A multiple, in plain terms, is the price tag per dollar of profit. IF 2025’s earnings level proved repeatable and IF the multiple reverted toward its decade median of 3.8, the arithmetic would point to a materially higher price; whether either condition holds depends on the reimbursement trajectory that management itself declined to forecast. The current gap between the two multiples reflects the market’s uncertainty about earnings repeatability, not necessarily a judgment that the underlying business is impaired.

For the standing yardsticks on Cormedix: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Cormedix.

Sources

  • 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
  • 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
  • Q3 2026 earnings call transcript (Motley Fool, November 12, 2026)
  • Q3 2026 financial results press release (GlobeNewswire, November 12, 2026)
  • Q3 2026 earnings call summary (MarketBeat, November 12, 2026)
  • Heron acquisition synergy targets (Seeking Alpha, November 2026)
  • Needham and RBC valuation estimate updates (MarketBeat, November 12, 2026)
  • CMS 2027 ESRD final rule and DefenCath add-on rate (Kalkine, 2026)
  • CorMedix business update and 2026 guidance reaffirmation (StockTitan)
  • DefenCath FDA approval (FiercePharma, November 2023)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read CorMedix’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Harrow’s Ledger: Revenue Held, Profits Didn’t

by Moe Alsumidaie
November 11, 2026
0

The quick read Harrow's management spent most of 2026 promising both strong revenue and strong profits. The filed numbers show they delivered on one and badly missed the...

Read moreDetails

The Quarter That Held Up, and the One Claim That Didn’t

by Moe Alsumidaie
November 6, 2026
0

Adaptive Biotechnologies spent six years losing money at a scale that would make most companies flinch. Then, on November 4, 2026, CEO Chad Robins called Q3 a "breakthrough...

Read moreDetails

CorMedix’s Scorecard: What Management Said, What the Filings Show, and Where the Story Gets Complicated

by Moe Alsumidaie
November 16, 2026
0

The quick read CorMedix spent years burning cash without a dollar of product revenue. Then DefenCath launched, and the filed numbers flipped almost overnight: the fiscal year 2025...

Read moreDetails

Lilly’s Ledger: The $4.2 Billion Footnote Management Hopes You Miss

by Moe Alsumidaie
October 30, 2026
0

A single acquisition charge, large enough to cut the company's earnings-per-share guidance even as management celebrated a revenue raise that left Wall Street cheering. That is what Eli...

Read moreDetails

Abbott’s Scorecard: What the Call Promised, What the Filings Show, and Where the Gap Lives

by Moe Alsumidaie
October 22, 2026
0

On the morning of October 21, 2026, Abbott's chief executive stepped onto a call with analysts and described a company growing in every direction. Four business segments, all...

Read moreDetails
Next Post

Arvinas: the first PROTAC approved, and almost nothing left to show for it

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Lowe’s Narrows the Range: What the Call Revealed That the Filing Couldn’t Hide

August 20, 2026

Lilly’s Ledger: The $4.2 Billion Footnote Management Hopes You Miss

October 30, 2026

Amgen: The Stock Is Priced for a Future the Patent Cliff Might Not Allow

October 26, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.